1. Introduction {#sec1}
===============

Upper urinary tract urothelial tumors represent approximately 5% of all urothelial tumors in the world \[[@B1]\]. However, 20--30% of all urothelial tumors are located in the upper tract in Taiwan \[[@B2]\]. The use of aristolochic acid contaminated Chinese herbal medicine has been reported to be associated with the high incidence of upper urinary tract urothelial carcinoma (UUT-UC) in Taiwan \[[@B3]\]. Radical nephroureterectomy (RNU) and bladder cuff resection is currently the standard treatment for localized UUT-UC \[[@B4]\]. Bladder recurrence has been mentioned as one of the major concerns with regard to oncological outcomes after RNU \[[@B5]\]. Bladder recurrence undoubtedly increases the disease burden and worsens the prognosis of UUT-UC after RNU. Therefore, regular cystoscopy follow-up after RNU is recommended in all UUT-UC patients \[[@B4]\]. However, cystoscopy itself is an invasive and costly procedure. It is thus extremely important to investigate the risk factors and identify those patients at high risk of bladder recurrence following RNU so that physicians can provide a closer follow-up schedule and adjuvant intravesical therapy to reduce bladder recurrence \[[@B6]\].

Numerous studies have been conducted to elucidate the prognostic factors for bladder recurrence after RNU for UUT-UC, although the results remain controversial \[[@B7]\]. Additionally, various bladder recurrence rates have been reported, ranging from 20 to 50% after RNU for primary UUT-UC \[[@B7]\]. Many of the results from previous studies vary because of inconsistencies in patient selection with regard to follow-up period or exclusion of prior bladder UC history \[[@B7]\].

This study aimed to retrospectively investigate patients with UUT-UC treated by RNU and bladder cuff resection to determine the impact of potential risk factors on subsequent bladder recurrence after RNU.

2. Materials and Methods {#sec2}
========================

From July 1994 to April 2012, a total of 695 patients with UUT-UC treated with RNU were enrolled in National Taiwan University Medical Center. Among them, 532 patients with no prior bladder UC history were recruited for final analysis. RNU was performed by open or laparoscopic method via transperitoneal or retroperitoneal route. Dissection of regional lymph nodes was performed in patients with suspicious lymphadenopathy on preoperative imaging studies or those suspected of having enlarged nodes during intraoperative inspection.

Clinical data were collected by a retrospective review of medical records. Follow-up included cystoscopy and urine cytology at three-month intervals for the first year, at six-month intervals for the subsequent two years, and then annually. Computed tomography and excretory urography were performed annually. Adjuvant systemic and intravesical chemotherapy were only administered in patients with the clinical evidence of recurrence. When bladder tumor was noted by cystoscopy or image follow-up, transurethral resection of the bladder tumor was performed. Recurrence was judged by histological proof. Pathological staging was performed according to the 2009 TNM staging system \[[@B4]\]. If carcinoma in situ existed concomitantly with Ta (noninvasive urothelial carcinoma), it would be classified as "Tis." However, if carcinoma in situ existed concomitantly with T1\~T4 (invasive urothelial carcinoma), it would be classified as T1 to T4 according to the most severe stage from all lesions of the specimen. Histological grading followed the 2004 World Health Organization grade classification \[[@B8]\].

The potentially prognostic factors assessed included age (older versus younger than 65 years), gender (male versus female), body mass index (BMI), pT stage (Ta-1, T2, T3-4, and Tis), grade (low versus high), tumor site (with versus without ureteral involvement), tumor multiplicity (yes versus no), residency in arsenic-endemic area (yes versus no), Chinese herbal medicine use (yes versus no), cigarette smoking (yes versus no), diabetes mellitus (DM) (yes versus no), hypertension (yes*versus* no), estimated glomerular filtration rate (eGFR) (\<60 mL/min versus ≥60 mL/min), hemodialysis history before RNU (yes versus no), operation method, and pN stage (N0 versus N1--3). The formula used to calculate BMI was body weight (kg)/body height squared (m^2^). Hypertension was defined as systolic blood pressure (SBP) ≥ 140 mmHg, diastolic blood pressure (DBP) ≥ 90 mmHg, or a history of hypertension in the subject\'s medical records. DM was defined as 2 h-PG ≥ 11.1 mmol/L, FPG ≥ 7.0 mmol/L, or a history of type 2 diabetes mellitus in the subject\'s medical records \[[@B9]\]. Multiplicity was defined as the presence of more than one tumor with healthy mucosa between them (≥two tumor foci). The prognostic implications of these factors with regard to bladder recurrence-free survival were analyzed. We defined "recurrence-free survival time" as the period between the date of the RNU for primary UUT-UC and the date of the first bladder recurrence.

Statistical analyses were performed using SPSS software (SPSS Inc., Chicago, IL, USA). Continuous data were expressed as mean ± standard deviation (SD), and percentages were calculated for categorical variables. The Mann-Whitney *U* test was used to compare the mean of continuous data, whereas the chi-square test was used to analyze categorical proportions. Univariate analyses and bladder recurrence-free survival curves were generated using the Kaplan-Meier method. Multivariate analyses were performed using Cox\'s proportional hazards model to estimate the hazard ratio and 95% confidence interval. Two-tailed *P* \< 0.05 was considered statistically significant.

3. Results {#sec3}
==========

A total of 532 patients with UUT-UC formed the study sample. The mean age was 65.3 ± 11.7 years. The median follow-up period was 47.8 months (range: 3--210). Bladder recurrence developed in 156 (29.3%) patients. [Table 1](#tab1){ref-type="table"} outlines the patients\' clinicopathological characteristics stratified by the presence of ureteral involvement. There were significant differences in tumor multiplicity (*P* \< 0.001), residence in arsenic-endemic area (*P* = 0.035), grading (*P* = 0.004), and pT stage (*P* \< 0.001) between the two groups, ureteral involvement versus no involvement. The mean time to bladder recurrence was 18.8 ± 27.0 months in the patients with ureteral involvement and 19.5 ± 24.4 months in those without it.

[Table 2](#tab2){ref-type="table"} shows the univariate and multivariate analyses for variables associated with subsequent bladder recurrence after RNU. The multivariate analyses revealed DM (HR: 1.821; *P* = 0.010) and ureteral involvement (HR: 1.838; *P* = 0.003) were significant risk factors associated with bladder recurrence. The Kaplan-Meier survival curve and log-rank test on bladder recurrence-free survival in UUT-UC patients stratified by the presence of ureteral involvement and DM are shown in Figures [1(a)](#fig1){ref-type="fig"} and [1(b)](#fig1){ref-type="fig"}, respectively. UUT-UC patients with ureteral involvement had a higher risk of bladder recurrence after RNU compared to those without it (*P* = 0.002). The one-, two-, and five-year bladder recurrence-free survival rates were 81%, 65%, and 57% in patients with ureteral involvement and 85%, 78%, and 72% in those without ureteral involvement, respectively. In addition, there were significant differences in bladder recurrence after RNU for UUT-UC between DM patients and non-DM subjects (*P* = 0.003).

We further analyzed the bladder recurrence-free survival in UUT-UC patients by substratification of the presence of ureteral involvement and DM. The results are shown in [Figure 1(c)](#fig1){ref-type="fig"}. The bladder recurrence-free survival was the worst in patients with concomitant diabetes and ureteral involvement, followed by those with one of the two risk factors. The prognosis was the best in those without any of the two risk factors. Patients with concomitant diabetes and ureteral UC had a significantly lower bladder recurrence-free survival rate as compared to those without any of the two risk factors (*P* \< 0.001). Similarly, patients with either of the two risk factors witnessed a significantly increased risk of bladder recurrence as compared to those without either of the two risk factors (with DM, *P* = 0.019; with ureteral involvement, *P* = 0.002, resp.). The five-year recurrence-free survival rate for patients with concomitant ureteral involvement and DM was 41% compared with 73% for patients without any of the two risk factors. [Table 3](#tab3){ref-type="table"} shows that patients with concomitant ureteral involvement and DM experienced about a threefold increased risk of developing bladder recurrence compared to those with neither of the two risk factors (HR: 3.222; *P* \< 0.001). Consistently, patients with either DM or ureteral involvement experienced an approximately twofold increased risk of developing bladder recurrence compared to those with neither of the risk factors (with DM, HR: 2.184, *P* = 0.024; with ureteral involvement, HR: 2.006, *P* = 0.003, resp.).

4. Discussion {#sec4}
=============

The present study identified two significant factors associated with bladder recurrence of UUT-UC after RNU: DM and ureteral involvement. The overall bladder recurrence rate in our study with long-term follow-up was 29.3%, consistent with the results of previous reports, which ranged from 20 to 50% \[[@B7]\]. In agreement with most previous studies, we also found that most of the bladder recurrence occurred within the first two years after RNU \[[@B10]\]. The National Comprehensive Cancer Network (NCCN) guidelines published in 2012 recommended cystoscopy and urinary cytology checkup every three months for one year and then at increasing intervals after NU for primary UUT-UC \[[@B11]\]. Our findings support the follow-up protocol recommended by NCCN. However, in UUT-UC patients with concomitant DM and ureteral involvement, a closer follow-up schedule and even adjuvant intravesical therapy may need to be considered, as they are at higher risk of bladder recurrence.

A history of bladder UC has been reported to be a significant risk factor for bladder recurrence after UUT-UC treatment in several previous studies \[[@B12]\]. We thus excluded patients with a prior history of bladder UC to minimize the bias from study subjects with primary UUT-UC. Moreover, our study subjects were representative of a special population in Taiwan, one which comes from an area with a high prevalence of UUT-UC. The etiologies responsible for the high prevalence of UUT-UC have been described as arsenic contaminated drinking water and the use of aristolochic-containing Chinese herbal medicine. Based on this, we included all potentially relevant risk factors in Taiwan, such as smoking, residency in an arsenic-endemic area, and use of Chinese herbal medicine, in order to determine all possible risk factors \[[@B13]--[@B15]\].

The association of DM and cancer occurrence has been described in various sites, such as liver, pancreas, colon, esophagus, kidney, blood, breast, endometrium, and bladder \[[@B16]\]. DM is considered to be a low-grade inflammation that is associated with reduced antioxidant capacity and an adverse secretory profile of cytokines \[[@B17]\]. Oxidative stress can result in genomic instability and DNA mutations, and cytokines such as interleukin 6, tumor necrosis factor-alpha, and plasminogen activator inhibitor-1 are thought to be involved in malignant transformation \[[@B18]--[@B20]\]. In addition, DM patients often tend to suffer from bacterial cystitis, and asymptomatic bacteriuria and symptomatic urinary tract infection are more common in DM women compared to healthy women \[[@B21]\]. Damaged urothelium and glycosaminoglycan and mucopolysaccharide layers on the surface of the urinary bladder may enhance the risk of UC cell adherence and implantation \[[@B22]\]. Both epidemiological \[[@B23]\] and animal studies \[[@B24]\] reveal that urinary tract infection has a significant impact on the subsequent occurrence of bladder cancer. On the other hand, the relationship between the use of insulin sensitizing peroxisome proliferator-activated receptor gamma agonists for the treatment of type II DM, such as pioglitazone, and the risk of bladder cancer is still under debate \[[@B25]\]. A study using the National Health Insurance database in Taiwan revealed that, among 422 patients using pioglitazone, none had developed bladder cancer during the three-year observation period \[[@B26]\]. However, the current study had no data on its diabetic subjects\' history of pioglitazone usage. Although DM is actually an independent predictor for bladder UC recurrence after RNU, the role that pioglitazone plays in the linkage between diabetes and bladder recurrence in our cohort thus remains unclear.

A number of studies have described the location of the primary tumor as a risk factor for oncological outcomes and subsequent bladder recurrence for UUT-UC. While some research has indicated that synchronous ureter and renal pelvic UC is a significant risk factor \[[@B27]--[@B30]\], others have found that tumor multiplicity is being a more important predictor than tumor locations \[[@B31], [@B32]\]. These inconsistent results may be due to variations in the definitions of multiplicity and location in the related literature. The current study showed that ureteral involvement increased the risk of bladder recurrence by 1.8-fold (HR: 1.838; *P* = 0.003). In contrast, multiplicity did not emerge as a significant predictor of bladder recurrence.

Two hypotheses have been proposed to explain subsequent bladder recurrence after RNU: intraluminal seeding and implantation of cancer cells and field cancerization \[[@B33]\]. Some molecular studies on UUT-UC and subsequent bladder recurrence suggest that seeding and intraepithelial spread are major mechanisms for the multifocal development of UC \[[@B34], [@B35]\]. We hypothesized that the underlying disease of DM creates a damaged mucosal layer over the bladder wall and that urothelial carcinoma located in the lower ureter facilitates tumor cell seeding to the bladder due to the adjacent location. These two factors thus increased the possibility of bladder recurrence.

A history of hemodialysis was found to have a borderline significant association with bladder recurrence in our cohort (multivariate analysis, HR: 1.791, *P* = 0.055). Previous studies have documented that end-stage renal disease (ESRD) patients on renal replacement therapy were at increased risk of urothelial carcinoma \[[@B36]\]. Residency in an arsenic-endemic area was not associated with the risk of bladder recurrence after RNU in the current study. An earlier study \[[@B2]\] had the same result, and this might be explained by the use of a tap water supply system (arsenic concentration 10 *μ*g/L) instead of artesian-well water (arsenic concentration 700 to 930 *μ*g/L) in our arsenic-endemic area since the early 1970s \[[@B37]\]. In contrast to previous reports, concomitant CIS was not significantly associated with bladder recurrence after RNU in our study. This could be due to the low incidence of CIS in our dataset compared to that in prior studies, indicating that the CIS prevalence rate was approximately 30% in UUT-UC \[[@B38]\].

This study has several limitations that should be taken into consideration. First, it was a retrospective study in a single center setting and some data was missing for some of the variables. We also lacked some detailed clinical information, such as diabetes duration and control, smoking status, being a current or former smoker, tumor size, the duration of residence in an arsenic-endemic area, and the methods of distal ureteral management used. In addition, pathological diagnosis was not performed by a central pathologist. However, this study utilized a large patient number, longer follow-up period, and homogeneous patient sample and thus is still able to provide important information which may be beneficial to clinicians and serve as a reference in relation to further studies.

5. Conclusions {#sec5}
==============

We identified ureteral involvement and DM as risk factors of bladder recurrence after RNU. Based on these findings, physicians can provide more individualized follow-up protocols and identify those patients who may benefit from prophylactic intravesical therapy according to the risk stratification.
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![Kaplan-Meier analysis on bladder recurrence-free survival, (a) kidney versus ureteral involvement, (b) diabetes mellitus (DM) versus non-DM, (c) stratification by the presence of ureteral involvement or DM.](BMRI2015-527976.001){#fig1}

###### 

Clinicopathological characteristics stratified by ureteral involvement in 532 patients with UUT-UC treated by RNU.

  Variable                           No ureteral involvement, *n* (%)   Ureteral involvement, *n* (%)   *P*
  ---------------------------------- ---------------------------------- ------------------------------- -------------
                                     299 (56.2)                         233 (43.8)                       
  Median follow-up period (months)   51.5                               43.9                            0.227
  Age (years)                                                                                           0.685
   \<65                              131 (43.8)                         98 (42.1)                        
   ≥65                               168 (56.2)                         135 (57.9)                       
  BMI (mean ± SD)                    24.3 ± 4.2                         23.5 ± 4.3                      0.185
  Gender                                                                                                0.533
   Male                              157 (52.5)                         116 (49.8)                       
   Female                            142 (47.5)                         117 (50.2)                       
  Residency                                                                                             0.035^\*^
   Nonarsenic                        295 (98.7)                         223 (95.7)                      
   Arsenic                           4 (1.3)                            10 (4.3)                        
  Smoking                                                                                               0.801
   No                                232 (78.1)                         176 (77.2)                       
   Yes                               65 (21.9)                          52 (22.8)                        
  Herb                                                                                                  0.058
   No                                174 (93.0)                         118 (86.8)                      
   Yes                               13 (7.0)                           18 (13.2)                       
  DM                                                                                                    0.132
   No                                158 (84.5)                         106 (77.9)                       
   Yes                               29 (15.5)                          30 (22.1)                        
  Hypertension                                                                                          0.363
   No                                122 (65.2)                         82 (60.3)                        
   Yes                               65 (34.8)                          54 (39.7)                        
  eGFR (mL/min)                                                                                         0.105
   \<60                              51 (33.3)                          30 (24.4)                        
   \>60                              102 (66.7)                         93 (75.6)                        
  Hemodialysis                                                                                          0.065
   No                                277 (92.6)                         204 (87.9)                       
   Yes                               22 (7.4)                           28 (12.1)                        
  Operation method                                                                                      0.236
   Open                                                                                                  
    Transperitoneal                  27 (23.5)                          14 (19.4)                        
    Retroperitoneal                  27 (23.5)                          27 (37.5)                        
   Laparoscopy                                                                                           
    Transperitoneal                  35 (30.4)                          18 (25.0)                        
    Retroperitoneal                  26 (22.6)                          13 (18.1)                        
  Multiplicity                                                                                          \<0.001^\*^
   No                                164 (87.7)                         91 (66.9)                        
   Yes                               23 (12.3)                          45 (33.1)                        
  Grade                                                                                                 0.004^\*^
   Low                               150 (54.9)                         86 (41.7)                        
   High                              123 (45.1)                         120 (58.3)                       
  T stage                                                                                               \<0.001^\*^
   Ta\~T1                            146 (56.4)                         87 (39.5)                        
   T2                                21 (8.1)                           62 (28.2)                        
   T3\~4                             89 (34.4)                          67 (30.5)                        
   Tis                               3 (1.2)                            4 (1.8)                          
  N stage                                                                                               0.278
   N0                                218 (90.5)                         182 (93.3)                       
   N1, N2, N3                        23 (9.5)                           13 (6.7)                         

Data expressed as mean ± SD or numbers (%), BMI: body mass index, DM: diabetes mellitus, eGFR: estimated glomerular filtration rate, nonarsenic: non-black-foot disease endemic area, and arsenic: black foot disease endemic area.

^\*^Significant difference, *P* \< 0.05.

###### 

Univariate and multivariate analyses for variables significantly associated with subsequent bladder recurrence after RNU in 532 patients with UUT-UC.

  Variable                      Univariate             Multivariate                          
  ----------------------------- ---------------------- -------------- ---------------------- -----------
  Age (years)                                                                                 
   \<65                         1                      ---                                    
   ≥65                          0.819 (0.594--1.128)   0.222                                  
  Gender                                                                                      
   Female                       1                      ---                                    
   Male                         1.210 (0.878--1.669)   0.245                                  
  Smoking                                                                                     
   No                           1                      ---                                    
   Yes                          1.221 (0.838--1.778)   0.298                                  
  BMI                           0.967 (0.909--1.028)   0.277                                  
  eGFR (mL/min)                                                                               
   \<60                         1                      ---                                    
   \>60                         1.347 (0.757--2.396)   0.312                                  
  Hemodialysis                                                                                
   No                           1                      ---            1                      ---
   Yes                          1.603 (0.990--2.595)   0.055          1.791 (0.988--3.244)   0.055
  Chinese herbal medicine use                                                                 
   No                           1                      ---            1                      ---
   Yes                          1.851 (1.012--3.386)   0.046^\*^      1.387 (0.731--2.632)   0.316
  Hypertension                                                                                
   No                           1                      ---                                    
   Yes                          1.292 (0.868--1.922)   0.207                                  
  DM                                                                                          
   No                           1                      ---            1                      ---
   Yes                          1.953 (1.241--3.074)   0.004^\*^      1.821 (1.152--2.878)   0.010^\*^
  Residency                                                                                   
   Nonarsenic                   1                      ---                                    
   Arsenic                      0.775 (0.247--2.434)   0.662                                  
  OP method                                                                                   
   Transperitoneal              1                      ---                                    
   Retroperitoneal              1.097 (0.674--1.786)   0.708                                  
  OP method                                                                                   
   Open                         1                      ---                                    
   Laparoscopy                  1.420 (0.868--2.323)   0.162                                  
  Grade                                                                                       
   Low                          1                      ---                                    
   High                         0.994 (0.705--1.402)   0.974                                  
  Ureteral involvement                                                                        
   No                           1                      ---            1                      ---
   Yes                          1.639 (1.189--2.260)   0.003^\*^      1.838 (1.233--2.741)   0.003^\*^
  Multiplicity                                                                                
   No                           1                      ---                                    
   Yes                          1.499 (0.953--2.356)   0.080                                  
  T stage                                                                                     
   Ta, 1                        1                      ---                                    
   T2                           1.135 (0.727--1.771)   0.578                                  
   T3, 4                        0.914 (0.610--1.368)   0.661                                  
   Tis                          2.110 (0.770--5.785)   0.147                                 
  N stage                                                                                     
   N0                           1                      ---                                    
   N1, 2, 3                     0.394 (0.125--1.239)   0.111                                  

BMI: body mass index, DM: diabetes mellitus, HR: Hazard ratio, and CI: confidence interval.

^\*^Significant difference, *P* \< 0.05.

###### 

The hazard ratio based on the presence of ureteral involvement and diabetes in the Kaplan-Meier analysis.

  Ureteral involvement   DM    *P*           HR      95% CI   
  ---------------------- ----- ------------- ------- -------- -------
  No                     No                  1                 
  No                     Yes   0.024^\*^     2.184   1.110    4.295
  Yes                    No    0.003^\*^     2.006   1.277    3.149
  Yes                    Yes   \<0.001^\*^   3.222   1.732    5.991

DM: diabetes mellitus, HR: Hazard ratio, and CI: confidence interval.

^\*^Significant difference, *P* \< 0.05.
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